MRK Rises $3 as Cramer Sees Path to $120 Amid JNJ Cancer Challenge
Jim Cramer highlights Merck’s recent stock recovery and potential upside after Johnson & Johnson challenges its oncology dominance. Merck & Co. (NYSE:MRK) gained $3 as Jim Cramer suggested the stock could rebound to $120. The move follows a strong quarterly report overshad